Esmo presentations of libtayo® (cemiplimab), fianlimab and novel bispecific antibodies showcase expanding potential of regeneron's oncology pipeline in multiple cancers

First-in-class phase 1 data for two investigational bispecifics in advanced ovarian cancer and advanced met-altered non-small cell lung cancer (nsclc) to be presented additional presentations include new data for investigational libtayo monotherapy and combination therapies in advanced melanoma, nsclc and cervical cancer, as well as neoadjuvant cutaneous squamous cell carcinoma regeneron will host an investor webcast on monday, september 12 at 8:00 am et to provide updates across its oncology portfolio tarrytown, n.y. , sept. 4, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that new and updated data across its oncology pipeline will be presented at the european society for medical oncology (esmo) congress 2022 from september 9 to 13 in paris.
REGN Ratings Summary
REGN Quant Ranking